AdociaXPAR:ADOC -1.60%30 EBITDA Margin % is -1,498.42% as of Dec. 2025. GuruFocus rates XPAR:ADOC with a GF Score™ of 30/100 and a GF Value™ of €0.91 (Significantly Overvalued). The stock has 7 warning signs investors should review. Among 944 Biotechnology companies, Adocia ranks worse than 79.77% on this metric.
EBITDA Margin % is calculated as EBITDA divided by its Revenue. Adocia's EBITDA for the
six
months ended in Dec. 2025 was €-6.65 Mil. Adocia's Revenue for the
six
months ended in Dec. 2025 was €0.44 Mil. Therefore, Adocia's EBITDA margin for the quarter that ended in Dec. 2025 was -1,498.42%.
Adocia (XPAR:ADOC) EBITDA Margin % Explanation
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Adocia EBITDA Margin % Related Terms
Adocia EBITDA Margin % Historical Data
* Premium members only.
The historical data trend for Adocia's EBITDA Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
XPAR:ADOC vs VRTX, REGN, ALNY: EBITDA Margin % Comparison
For the Biotechnology subindustry, Adocia's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Adocia EBITDA Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Adocia's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where Adocia's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Adocia (XPAR:ADOC) has a EBITDA Margin % of -1,498.42% as of Dec. 2025. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Adocia and its competitors. According to the industry distribution chart, Adocia ranks #753 out of 944 companies in the Biotechnology industry, placing it in the top 79.8%.
Is Adocia's EBITDA Margin % too high?
Adocia's current EBITDA Margin % is -1,498.42%. Based on the distribution chart, Adocia ranks #753 out of 944 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Adocia has a GF Score™ of 30/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Adocia's EBITDA Margin % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Adocia ranks #753 out of 944 companies for EBITDA Margin %. This places Adocia in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Biotechnology company?
A good EBITDA Margin % depends on the Biotechnology industry context. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Adocia and its competitors. Adocia's current EBITDA Margin % is -1,498.42%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Adocia stock overvalued right now?
Based on GuruFocus' analysis, Adocia (XPAR:ADOC) is currently considered Significantly Overvalued. The stock's GF Value™ is €0.91, compared to a current price of €3.94 — trading 332.7% above its estimated fair value. The current EBITDA Margin % is -1,498.42%. Adocia's overall GF Score™ is 30/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Adocia (XPAR:ADOC), the current EBITDA Margin % is -1,498.42% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Adocia (XPAR:ADOC) Overvalued in 2026?
Based on GuruFocus' analysis, Adocia stock appears to be overvalued.
The current stock price of €3.94 is trading 332.7% above its estimated GF Value™ of €0.91.
GuruFocus considers Adocia to be Significantly Overvalued.
Key valuation signals for XPAR:ADOC:
EBITDA Margin %: -1,498.42%
GF Value™: €0.91 vs. price of €3.94 (332.7% above fair value)
No single metric tells the full story. See the XPAR:ADOC stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Adocia is a clinical-stage biotechnology company. It specializes in the development of formulations of already approved therapeutic proteins and peptides for the treatment of diabetes and other metabolic diseases. The firm has developed Biochaperone, a proprietary technology platform to enhance the effectiveness of therapeutic proteins. The company's clinical pipeline includes Biochaperone Lispro, Biochaparone Combo, Biochaparone Glucagon, and others. Its pre-clinical pipeline includes BioChaperone LisPram, BioChaperone Glargine GLP-1, and BioChaperone Glucagon GLP1. Its patent portfolio mainly consists of chronic wound healing, insulin therapy, and monoclonal antibodies.
30GF Score
Get the complete analysis for XPAR:ADOC
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XPAR:ADOC has been successfully added to your 
